ARGOS THERAPEUTICS INC 4
4 · ARGOS THERAPEUTICS INC · Filed Feb 12, 2014
Insider Transaction Report
Form 4
Abbey Jeffrey D
DirectorChief Executive Officer
Transactions
- Conversion
Common Stock
2014-02-12+1,238→ 1,313 total - Conversion
Series C Preferred Stock
2014-02-12−75→ 0 total→ Common Stock (75 underlying) - Conversion
Series D Preferred Stock
2014-02-12−1,238→ 0 total→ Common Stock (1,238 underlying) - Conversion
Series E Preferred Stock
2014-02-12−1,267→ 0 total→ Common Stock (1,267 underlying) - Conversion
Common Stock
2014-02-12+75→ 75 total - Conversion
Common Stock
2014-02-12+1,267→ 2,580 total
Footnotes (3)
- [F1]Each share of Series C Preferred Stock converted into 0.0074 shares of common stock upon the closing of the Issuer's initial public offering of common stock for no additional consideration. The Series C Preferred Stock has no expiration date.
- [F2]Each share of Series D Preferred Stock converted into 0.1667 shares of common stock upon the closing of the Issuer's initial public offering of common stock for no additional consideration. The Series D Preferred Stock has no expiration date.
- [F3]Each share of Series E Preferred Stock converted into 0.1667 shares of common stock upon the closing of the Issuer's initial public offering of common stock for no additional consideration. The Series E Preferred Stock has no expiration date.